Jagsonpal Pharmaceuticals Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. For the third quarter of FY26, the company reported a revenue of ₹729 Mn, a slight decrease of 1% year-on-year. Operating EBITDA stood at ₹166 Mn, with an EBITDA margin of 22.7%. Profit After Tax (PAT) for the quarter increased by 10% to ₹125 Mn, with margins expanding by 160 basis points to 17.1%. For the nine months ended December 31, 2025, revenue grew by 6% year-on-year to ₹2,230 Mn. Operating EBITDA for the nine-month period increased by 5% to ₹503 Mn, maintaining a margin of 22.6%. The Profit After Tax (PAT) for the nine months surged by 12.5% to ₹359 Mn, with operating PAT margins expanding by 95 basis points to 16.1%. The company highlighted a robust free cash generation, with its cash balance reaching ₹1,757 Mn as of December 31, 2025, an increase of ₹152 Mn during the quarter. Manish Gupta, Managing Director and CEO, expressed confidence in stronger future growth, starting from Q4 of the current fiscal, supported by strategic initiatives and a strong balance sheet.
